We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical intellectual property rights remain a significant sticking point in a proposed draft of the massive Trans-Pacific Partnership (TPP) trade pact leaked last week. Read More
Two lawmakers wrote to HHS Secretary Sylvia Burwell seeking an analysis of national drug pricing and efforts by the Obama administration to bring rising generic prices under control. The letter is likely a precursor to congressional hearings. Read More
Pfizer is the latest company to win approval of opioid abuse-deterrent labeling, after the FDA cautiously okayed new statements about Embeda late Friday. Read More
The European Medicines Agency is urging companies developing drugs and vaccines for Ebola to seek orphan designation to hasten the evaluation of applications for products that could help victims of the current outbreak in West Africa. Read More
The UK’s healthcare cost agency affirmed its June recommendation to cover Novartis’ cancer drug Glivec as an adjuvant treatment for patients at high risk of post-surgery recurrence of gastrointestinal stromal tumors. Read More
The European Medicines Agency has approved Janssen and Pharmacyclics’ blood cancer drug Imbruvica for two indications, a move that follows similar approvals in the U.S. this summer. Read More
Amgen is looking to head off future competition to a high cholesterol therapy, evolocumab, that hasn’t even been approved yet, with a patent infringement lawsuit against fellow biologics makers Sanofi and Regeneron. Read More
Spectrum Pharmaceuticals wants an extra four months of market exclusivity on its cancer drug Fusilev, arguing the FDA’s delay in approving the drug’s name entitles it to a revised approval clock. Read More
Canadian generics makers have promised to cap the costs of 18 top-selling, high-volume products to 18 percent of their brand reference’s price, under a sweeping drug pricing deal that will result in a roughly $3.8 billion industry-wide revenue reduction. Read More
The FDA’s proposal that drugmakers add microbiology and pharmacogenics information to product labels should apply only to new prescription drugs and biologics, said industry experts. Read More